Treatment of chronic COVID ‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34988 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Maike Janssen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms, SARS-CoV-2, Immunization, Passive. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federal Ministry of Education and Research, Germany, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Immunocompromised patients are at high risk to fail clearance of SARS‐CoV‐2. Prolonged COVID‐19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS‐CoV‐2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS‐CoV‐2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID‐19 infection. Here, we report on a series of 21 immunocompromised patients with COVID‐19—most of them hematologic malignancies—treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS‐CoV‐2‐antibody‐containing plasma could clear SARS‐CoV‐2 infection in 16 out of 21 immunocompromised patients even if COVID‐19‐specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS‐CoV‐2 infection. Ten patients were major responders defined as an increase delta( d ) Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS‐CoV‐2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10–24.25) to a median value of 29.57 (IQR = 27.55–34.63; p =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
- Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany.
- Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany.
- NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), Heidelberg, Germany.
- Division of Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
ORCID-Profile: Maike Janssen, Michael Schmitt
Förderung
- Federal Ministry of Education and Research, Germany
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Janssen, M., Leo, A., Wolf, C., Stenzinger, M., Bartenschlager, M., Brandt, J., Sauer, S., Schmitt, M., Dreger, P., Schlenk, R. F., Denkinger, C. M., & Müller-Tidow, C. (2024). Treatment of chronic COVID ‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies. International Journal of Cancer. https://doi.org/10.1002/ijc.34988
Vancouver
Janssen M, Leo A, Wolf C, Stenzinger M, Bartenschlager M, Brandt J, et al. Treatment of chronic COVID ‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies. International Journal of Cancer. 2024. doi:10.1002/ijc.34988
BibTeX
@article{Janssen2024,
author = {Janssen, Maike and Leo, Albrecht and Wolf, Cornelia and Stenzinger, Miriam and Bartenschlager, Marie and Brandt, Juliane and Sauer, Sandra and Schmitt, Michael and Dreger, Peter and Schlenk, Richard F and Denkinger, Claudia M and Müller-Tidow, Carsten},
title = {Treatment of chronic COVID ‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34988}
}
EUVIMED